Magnum Ice Cream 1Q26 OSG Beat: Volume Recovery Across All Regions Validates Standalone Execution

Core Thesis

Magnum Ice Cream (MICCT.AS) reported 1Q26 organic sales growth of +4.5%, beating consensus (+2.7%) and reversing 4Q25’s -0.7%. Volume growth of +2.9% vs. consensus +0.5% drove the beat, with all three regions outperforming: Europe & ANZ +4.0% (cons. +1.1%), Americas +2.6% (cons. +1.4%), and AMEA +7.9% (cons. +7.1%). Management maintained full-year OSG guidance (+3-5%) and margin expansion (+40-60bps comparable). The stock trades at 12x CY26e P/E, a 25% discount to European Staples (16x), despite a 9.7% EPS CAGR (2026-29E) vs. 7.5% for peers. This discount should narrow as the market prices volume recovery durability and second-half margin acceleration.

What the Market May Be Underpricing

Three factors are underappreciated. First, the breadth of the volume beat (+2.9% vs. +0.5% consensus) indicates consumer acceptance of innovation and pricing is stronger than feared. Second, margin guidance is conservative: cost savings and TSA exit (scheduled for end-2027) are on track, and the India acquisition (closed March 30) adds high-growth, margin-accretive exposure. Third, AMEA growth (+7.9%, volume +4.9%) and Brazil’s turnaround provide structural upside ignored at 12x earnings.

Evidence Chain

1Q26 OSG beat was broad-based. Group OSG +4.5% beat VA consensus by 180bps. Volume +2.9% vs. cons +0.5% and 4Q25’s -3.0%. Price +1.6% undershot cons +2.2%, implying mix/innovation rather than pure pricing. Europe & ANZ OSG +4.0%, volume +4.3% (cons -0.1%), driven by Germany and UK (+HSD% each). Americas OSG +2.6% (cons +1.4%) with US brands Yasso and Popsicle +DD% and Ben & Jerry’s +LSD%. AMEA OSG +7.9% (cons +7.1%) led by Turkiye and Pakistan (+DD%) and China (+HSD%). FX headwinds of -5.5% on revenue but OSG unaffected.

Guidance maintained, 2H weighted. FY26 OSG guide +3-5% (cons +3%), Adj. EBITDA margin +40-60bps comparable. Margin development is 2H weighted. Cost savings on track, TSA exit by end-2027. India acquisition immaterial in 1Q, expected to contribute in 2H. FX guidance narrowed to -2.2% from -3.1%, a tailwind.

Brand health solid. Magnum +MSD% (FY25 +HSD%), The Heartbrand +HSD% (FY25 +LSD%), Ben & Jerry’s flat. Moderation in Magnum is in line with tough comparisons.

Valuation case strong. At €11.16, 12x CY26e P/E vs. 16x for EU Staples. EPS CAGR 9.7% (2026-29E) vs. 7.5% peers. Target price €16.1 (44% upside) blends DCF (€18.3, 8.3% WACC, 2.0% terminal growth) and P/E (€13.8, 14.9x NTM, a 15% discount to EU Staples reflecting limited track record). This discount should compress as execution track record builds.

Key Risks

Structural health-and-wellness trends could dent category growth. Competitive intensity may pressure margins and OSG. Separation costs or TSA exit delays could weigh on profits. FX volatility in Turkey, Brazil, and China remains a headwind. India acquisition integration carries execution risk.

Valuation & Trade Implications

At 12x CY26e P/E with a 9.7% EPS CAGR, Magnum offers a rare combination of cheapness and growth in European staples. The 1Q26 beat, with volume inflection across all regions, reduces the risk that consensus is too optimistic. We recommend Overweight with a €16.1 target. Catalysts: 2H margin delivery, India acquisition details, continued AMEA/US volume momentum.